Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Purchases $13,800.00 in Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp purchased 15,000 shares of the stock in a transaction dated Monday, February 24th. The shares were purchased at an average price of $0.92 per share, with a total value of $13,800.00. Following the transaction, the director now directly owns 176,141 shares of the company’s stock, valued at approximately $162,049.72. The trade was a 9.31 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Clearside Biomedical Price Performance

NASDAQ CLSD opened at $0.90 on Thursday. Clearside Biomedical, Inc. has a 12 month low of $0.80 and a 12 month high of $2.12. The firm has a market capitalization of $68.26 million, a PE ratio of -2.00 and a beta of 2.22. The company’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $1.06.

Hedge Funds Weigh In On Clearside Biomedical

Hedge funds have recently modified their holdings of the company. Investor s Fiduciary Advisor Network LLC bought a new stake in shares of Clearside Biomedical in the 4th quarter worth $32,000. Johnson & Johnson acquired a new position in Clearside Biomedical during the third quarter worth about $105,000. Northern Trust Corp raised its position in Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after acquiring an additional 32,048 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Clearside Biomedical by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 731,386 shares of the company’s stock valued at $929,000 after acquiring an additional 59,089 shares during the last quarter. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CLSD has been the subject of a number of analyst reports. Chardan Capital reissued a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Wednesday, November 13th. Finally, StockNews.com raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.33.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.